• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Zimmer Biomet Holdings Inc. (Amendment)

    11/7/22 1:32:39 PM ET
    $ZBH
    Industrial Specialties
    Health Care
    Get the next $ZBH alert in real time by email
    SC 13G/A 1 ZIMMER_BIOMET_HOLDINGS_INC.htm FILING ZIMMER BIOMET HOLDINGS, INC. Schedule 13G


     
    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
     
    SCHEDULE 13G
     
     
    Under the Securities Exchange Act of 1934
    (Amendment No. 01)*
     
    ZIMMER BIOMET HOLDINGS, INC. 

    (Name of Issuer)
     
    Common Stock, $0.01 par value

    (Title of Class of Securities)
     
    98956P102

    (CUSIP Number)
     
    October 31, 2022

    (Date of Event Which Requires Filing of this Statement)
     
    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
     
         x  Rule 13d-1(b)
     
         o  Rule 13d-1(c)
     
         o  Rule 13d-1(d)
     
    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.
     
    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
     


     
     

     
     
    CUSIP No.  98956P102            
     
               
    1   NAMES OF REPORTING PERSONS

    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
      JPMORGAN CHASE & CO.

    13-2624428
         
    2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)



      (a)   o
      (b)   o
         
    3   SEC USE ONLY
       
       
         
    4   CITIZENSHIP OR PLACE OF ORGANIZATION
       
      Delaware
           
    NUMBER OF SHARES BENEFICIALLY  OWNED BY EACH REPORTING PERSON WITH:  5   SOLE VOTING POWER
       
      4,822,751
         
    6   SHARED VOTING POWER
       
      36,923
         
    7   SOLE DISPOSITIVE POWER
       
      5,070,500
         
    8   SHARED DISPOSITIVE POWER
       
      18,111
         
    9   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
       
      5,091,869
         
    10   CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
       
      o
         
    11   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
       
      2.4 %
         
    12   TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
       
      HC
     

    FOOTNOTES
       
     
     
     

     
     
    Item 1.


     
    (a)
    Name of Issuer
     
     
    ZIMMER BIOMET HOLDINGS, INC.


     
    (b)
    Address of Issuer’s Principal Executive Offices
     
     
    345 East Main Street
    Warsaw, IN 46580


    Item 2.


     
    (a)
    Name of Person Filing
     
     
    JPMORGAN CHASE & CO.


     
    (b)
    Address of Principal Business Office or, if none, Residence
     
     
    383 Madison Avenue
    New York, NY 10179


     
    (c)
    Citizenship
     
     
    Delaware


     
    (d)
    Title of Class of Securities
     
     
    Common Stock, $0.01 par value


     
    (e)
    CUSIP Number
     
     
    98956P102


     
    Item 3.
    If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:


     
    (a)
    o
    Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).


     
    (b)
    o
    Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).


     
    (c)
    o
    Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).


     
    (d)
    o
    Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C 80a-8).


     
    (e)
    o
    An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);


     
    (f)
    o
    An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);


     
    (g)
    x
    A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);


     
    (h)
    o
    A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);


     
    (i)
    o
    A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);


     
    (j)
    o
    A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J).


     
    (k)
    o
    A group, in accordance with § 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:


     
     
     

     
     
    Item 4.
    Ownership.
     
    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.


     
    (a)
    Amount beneficially owned: 5,091,869


     
    (b)
    Percent of class: 2.4 %


     
    (c)
    Number of shares as to which the person has:


     
    (i)
    Sole power to vote or to direct the vote: 4,822,751


     
    (ii)
    Shared power to vote or to direct the vote: 36,923


     
    (iii)
    Sole power to dispose or to direct the disposition of: 5,070,500


     
    (iv)
    Shared power to dispose or to direct the disposition of: 18,111


    Item 5.
    Ownership of Five Percent or Less of a Class
     
    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following x .
     
     
     
    Item 6.
    Ownership of More than Five Percent on Behalf of Another Person.
     
    Not Applicable
     
    Item 7.
    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company
     
    J.P. Morgan Investment Management Inc.
    JPMorgan Chase Bank, National Association
    JPMorgan Asset Management (UK) Limited
    J.P. Morgan (Suisse) SA
    J.P. Morgan Trust Company of Delaware
    J.P. Morgan Securities LLC
    JPMorgan Asset Management (Asia Pacific) Limited
    55I, LLC
    J.P. MORGAN SE
     
    Item 8.
    Identification and Classification of Members of the Group
     
    Not Applicable
     
    Item 9.
    Notice of Dissolution of Group
     
    Not Applicable
     
     
     

     
     
     
    Item 10.
    Certification
       
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a-11.
     
     


    SIGNATURE


    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
     
     
      JPMORGAN CHASE & CO.

     
           
    Date: November 07, 2022
    By:
    /s/  Rachel Tsvaygoft  
        Name: Rachel Tsvaygoft  
        Title:  Vice President  
           
     
    Footnotes:


    Attention:
    Intentional misstatements or omissions of fact constitute Federal criminal violations (See 18 U.S.C. 1001)
     
     



    Get the next $ZBH alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ZBH

    DatePrice TargetRatingAnalyst
    12/17/2024$125.00 → $128.00Neutral → Overweight
    Analyst
    9/10/2024Peer Perform
    Wolfe Research
    7/1/2024$140.00 → $115.00Overweight → Neutral
    Piper Sandler
    5/30/2024$129.00Neutral
    Goldman
    5/21/2024$150.00Hold → Buy
    Argus
    1/4/2024$135.00 → $125.00Outperform → In-line
    Evercore ISI
    10/20/2023$120.00Neutral
    ROTH MKM
    8/28/2023$139.00Neutral → Buy
    BTIG Research
    More analyst ratings

    $ZBH
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Zimmer Biomet to Present at the Goldman Sachs 46th Annual Global Healthcare Conference

      WARSAW, Ind., May 22, 2025 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) today announced that members of the Zimmer Biomet management team will be presenting at the Goldman Sachs 46th Annual Global Healthcare Conference on Monday, June 9, 2025, at 9:20 a.m. ET. A live webcast of the presentation can be accessed via Zimmer Biomet's Investor Relations website at https://investor.zimmerbiomet.com. The webcast will be archived for replay following the conference. About Zimmer Biomet  Zimmer Biomet is a global medical technology leader with a comprehensive portfo

      5/22/25 7:30:00 AM ET
      $ZBH
      Industrial Specialties
      Health Care
    • Zimmer Biomet Announces First Quarter 2025 Financial Results

      First quarter net sales of $1.909 billion increased 1.1% and 2.3% on a constant currency1 basisFirst quarter diluted earnings per share were $0.91; adjusted1 diluted earnings per share were $1.81Company updates full-year 2025 reported revenue guidance to include the Paragon 28 acquisition and currency expectations, and full-year 2025 adjusted1 earnings per share guidance to include Paragon 28, currency and the impact from current tariff proposalsWARSAW, Ind., May 5, 2025 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) today reported financial results for the quarter ended March 31, 2025.  The Company reported first quarter net sales of $1.909 billion, an increase of 1.1% ove

      5/5/25 6:30:00 AM ET
      $ZBH
      Industrial Specialties
      Health Care
    • Zimmer Biomet Completes Acquisition of Paragon 28

      Transaction Further Strengthens Company's Position in High-Growth Foot and Ankle Segment WARSAW, Ind., April 21, 2025 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. ("Zimmer Biomet"; NYSE and SIX: ZBH), a global medical technology leader, today announced it has completed the acquisition of Paragon 28, Inc. ("Paragon 28"), a leading medical device company focused exclusively on the fast-growing foot and ankle orthopedic space. "We look forward to building on the strong foundation set by Albert DeCosta and the Paragon 28 team and are excited to officially welcome them to the Zimm

      4/21/25 9:00:00 AM ET
      $ZBH
      Industrial Specialties
      Health Care

    $ZBH
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Zimmer Biomet Holdings Inc.

      SC 13G - ZIMMER BIOMET HOLDINGS, INC. (0001136869) (Subject)

      11/14/24 1:22:34 PM ET
      $ZBH
      Industrial Specialties
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Zimmer Biomet Holdings Inc.

      SC 13G/A - ZIMMER BIOMET HOLDINGS, INC. (0001136869) (Subject)

      11/13/24 1:44:56 PM ET
      $ZBH
      Industrial Specialties
      Health Care
    • SEC Form SC 13G filed by Zimmer Biomet Holdings Inc.

      SC 13G - ZIMMER BIOMET HOLDINGS, INC. (0001136869) (Subject)

      2/14/24 10:02:59 AM ET
      $ZBH
      Industrial Specialties
      Health Care

    $ZBH
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Jafry Syed A. bought $223,641 worth of shares (2,135 units at $104.75), increasing direct ownership by 111% to 4,060 units (SEC Form 4)

      4 - ZIMMER BIOMET HOLDINGS, INC. (0001136869) (Issuer)

      11/13/23 4:02:02 PM ET
      $ZBH
      Industrial Specialties
      Health Care
    • Begley Christopher B bought $117,114 worth of shares (1,000 units at $117.11), increasing direct ownership by 39% to 3,540 units (SEC Form 4)

      4 - ZIMMER BIOMET HOLDINGS, INC. (0001136869) (Issuer)

      9/29/23 4:05:41 PM ET
      $ZBH
      Industrial Specialties
      Health Care

    $ZBH
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Officer Noor Jehanzeb

      4 - ZIMMER BIOMET HOLDINGS, INC. (0001136869) (Issuer)

      4/3/25 5:06:51 PM ET
      $ZBH
      Industrial Specialties
      Health Care
    • SEC Form 4 filed by Director Farrell Michael J.

      4 - ZIMMER BIOMET HOLDINGS, INC. (0001136869) (Issuer)

      4/2/25 8:40:00 PM ET
      $ZBH
      Industrial Specialties
      Health Care
    • SEC Form 4 filed by Director Begley Christopher B

      4 - ZIMMER BIOMET HOLDINGS, INC. (0001136869) (Issuer)

      4/2/25 4:11:50 PM ET
      $ZBH
      Industrial Specialties
      Health Care

    $ZBH
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Zimmer Biomet upgraded by Analyst with a new price target

      Analyst upgraded Zimmer Biomet from Neutral to Overweight and set a new price target of $128.00 from $125.00 previously

      12/17/24 8:26:36 AM ET
      $ZBH
      Industrial Specialties
      Health Care
    • Wolfe Research initiated coverage on Zimmer Biomet

      Wolfe Research initiated coverage of Zimmer Biomet with a rating of Peer Perform

      9/10/24 8:03:41 AM ET
      $ZBH
      Industrial Specialties
      Health Care
    • Zimmer Biomet downgraded by Piper Sandler with a new price target

      Piper Sandler downgraded Zimmer Biomet from Overweight to Neutral and set a new price target of $115.00 from $140.00 previously

      7/1/24 7:51:41 AM ET
      $ZBH
      Industrial Specialties
      Health Care

    $ZBH
    Financials

    Live finance-specific insights

    See more
    • Zimmer Biomet Announces First Quarter 2025 Financial Results

      First quarter net sales of $1.909 billion increased 1.1% and 2.3% on a constant currency1 basisFirst quarter diluted earnings per share were $0.91; adjusted1 diluted earnings per share were $1.81Company updates full-year 2025 reported revenue guidance to include the Paragon 28 acquisition and currency expectations, and full-year 2025 adjusted1 earnings per share guidance to include Paragon 28, currency and the impact from current tariff proposalsWARSAW, Ind., May 5, 2025 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) today reported financial results for the quarter ended March 31, 2025.  The Company reported first quarter net sales of $1.909 billion, an increase of 1.1% ove

      5/5/25 6:30:00 AM ET
      $ZBH
      Industrial Specialties
      Health Care
    • Zimmer Biomet Completes Acquisition of Paragon 28

      Transaction Further Strengthens Company's Position in High-Growth Foot and Ankle Segment WARSAW, Ind., April 21, 2025 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. ("Zimmer Biomet"; NYSE and SIX: ZBH), a global medical technology leader, today announced it has completed the acquisition of Paragon 28, Inc. ("Paragon 28"), a leading medical device company focused exclusively on the fast-growing foot and ankle orthopedic space. "We look forward to building on the strong foundation set by Albert DeCosta and the Paragon 28 team and are excited to officially welcome them to the Zimm

      4/21/25 9:00:00 AM ET
      $ZBH
      Industrial Specialties
      Health Care
    • Zimmer Biomet Announces Webcast and Conference Call of First Quarter 2025 Financial Results

      WARSAW, Ind., April 10, 2025 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) today announced its first quarter earnings conference call will be webcast on Monday, May 5, 2025, at 8:30 a.m. ET. A news release detailing the quarterly results will be made available that day at 6:30 a.m. ET. The live audio webcast can be accessed via Zimmer Biomet's Investor Relations website at https://investor.zimmerbiomet.com. It will be available for replay following the conference call. Individuals in the U.S. and Canada who wish to dial into the conference call may do so by

      4/10/25 7:30:00 AM ET
      $ZBH
      Industrial Specialties
      Health Care

    $ZBH
    Leadership Updates

    Live Leadership Updates

    See more
    • Zimmer Biomet Names Kristen Cardillo as Senior Vice President, Chief Communications Officer

      WARSAW, Ind., March 6, 2025 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced the appointment of Kristen Cardillo as Senior Vice President, Chief Communications Officer. Reporting to President and CEO Ivan Tornos, Ms. Cardillo will join the Company on March 10, 2025, to lead Zimmer Biomet's global communications strategy, enhancing engagement with key stakeholders and amplifying the Company's position as a leader in MedTech. "Kristen's expertise in shaping compelling corporate narratives and leading high-impac

      3/6/25 7:30:00 AM ET
      $ZBH
      Industrial Specialties
      Health Care
    • Zimmer Biomet Appoints Jehanzeb Noor as Senior Vice President, Chief Strategy, Innovation and Business Development Officer

      WARSAW, Ind., Feb. 27, 2025 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced that Jehanzeb Noor is joining the Company as Senior Vice President, Chief Strategy, Innovation and Business Development Officer. He will report to Ivan Tornos, President and CEO of Zimmer Biomet. In his new role, Mr. Noor will be responsible for leading strategy development and execution and all facets of M&A, including the integration for our pending acquisition of Paragon 28. In addition, he will have oversight of the research and

      2/27/25 7:30:00 AM ET
      $ZBH
      Industrial Specialties
      Health Care
    • Zimmer Biomet Announces Upcoming Changes to Company's Board of Directors

      WARSAW, Ind., Feb. 25, 2025 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced upcoming changes to the Company's Board of Directors, including:  Non-Executive Chairman of the Board Christopher Begley will retire from the Board of Directors at the Company's annual meeting of stockholders on May 29, 2025, pursuant to the mandatory director retirement age in the Company's Corporate Governance Guidelines;President and CEO Ivan Tornos will become Chairman of the Board upon Mr. Begley's retirement; andMichael Farrell

      2/25/25 4:05:00 PM ET
      $ZBH
      Industrial Specialties
      Health Care

    $ZBH
    SEC Filings

    See more
    • SEC Form SD filed by Zimmer Biomet Holdings Inc.

      SD - ZIMMER BIOMET HOLDINGS, INC. (0001136869) (Filer)

      5/23/25 7:00:04 AM ET
      $ZBH
      Industrial Specialties
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Zimmer Biomet Holdings Inc.

      SCHEDULE 13G/A - ZIMMER BIOMET HOLDINGS, INC. (0001136869) (Subject)

      5/6/25 4:46:12 PM ET
      $ZBH
      Industrial Specialties
      Health Care
    • SEC Form 10-Q filed by Zimmer Biomet Holdings Inc.

      10-Q - ZIMMER BIOMET HOLDINGS, INC. (0001136869) (Filer)

      5/5/25 4:00:26 PM ET
      $ZBH
      Industrial Specialties
      Health Care